Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

European Research Council grant · Running

LiveRNA Liver mRNA-based immunotherapies

Coordinator
Universita Vita-Salute San Raffaele, Italy
Runs
1 September 2026 to 29 February 2028
Status
Running
EU funding
€150k
Total cost
—
Partners
2 organisations in 2 countries
Type
European Research Council grant
Grant agreement
101335535

What the project is doing

In the project's own words, from its summary on CORDIS.

Primary liver cancer is the third cause of cancer-related death worldwide with about 900 000 new cases and 830 000 deaths worldwide each year and a 5-year survival of only 20%. Current systemic treatments, including checkpoint inhibitors and tyrosine kinase inhibitors, benefit only a minority of patients, and around 70% of FGF19-positive HCCs remain refractory to immunotherapy. In this PoC project, LiveRNA will develop a first-in-class liver-targeted mRNA platform.

It will combine mRNA-cGAS with a hepatocyte-specific IL-2 mRNA construct. This construct reprograms dysfunctional intrahepatic CD8 T-cells into potent antitumor effectors. LiveRNA will demonstrate the safety and antitumoral activity of the mRNA-cGAS/mRNA-IL-2 combination in stringent preclinical models, benchmark it against standard of care, and define the most promising HCC (and related liver tumour) subtypes for clinical translation.

We will also provide a rationale for patient selection and future combination regimens. In parallel, the LiveRNA team will consolidate a freedom-to-operate-based IP position on mRNA-cGAS and IL-2-mRNA, establish a dedicated spin-off company, LiveRNA, and engage with investors and industrial partners to accelerate first-in-human development of this scalable, low-dose, liver-specific immunotherapy for patients with otherwise untreatable HCC.

Topics

Who is involved

OrganisationCityCountryRole
Universita Vita-Salute San RaffaeleMilanoItalyCoordinator
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI